Role of exercise intensity on GLUT4 content, aerobic fitness and fasting plasma glucose in type 2 diabetic mice

2015 ◽  
Vol 33 (7) ◽  
pp. 435-442 ◽  
Author(s):  
Verusca Najara Cunha ◽  
Mérica de Paula Lima ◽  
Daisy Motta-Santos ◽  
Jorge Luiz Pesquero ◽  
Rosangela Vieira de Andrade ◽  
...  
Diabetes Care ◽  
1999 ◽  
Vol 22 (3) ◽  
pp. 394-398 ◽  
Author(s):  
R. L. Ollerton ◽  
R. Playle ◽  
K. Ahmed ◽  
F. D. Dunstan ◽  
S. D. Luzio ◽  
...  

Neurology ◽  
2017 ◽  
Vol 88 (10) ◽  
pp. 944-951 ◽  
Author(s):  
Chun-Pai Yang ◽  
Chia-Ing Li ◽  
Chiu-Shong Liu ◽  
Wen-Yuan Lin ◽  
Kai-Lin Hwang ◽  
...  

Objective:To examine whether variations in fasting plasma glucose (FPG), as measured by the coefficient of variation (CV), is a predictor of diabetic polyneuropathy (DPN) risk, considering glycated hemoglobin (HbA1c) and other traditional risk factors.Methods:Type 2 diabetic patients enrolled in the National Diabetes Care Management Program were ≥30 years of age and free of DPN (n = 36,152). They were enrolled in 2002–2004 and were monitored until 2011. The related factors were analyzed using Cox proportional hazards regression models.Results:During an average 7.23 years of follow-up, a total of 7,219 incident cases of DPN were identified, with a crude incidence rate of 27.62/1,000 person-years (25.83 for men and 29.31 for women). After multivariate adjustment, both FPG-CV and HbA1c were significant predictors of DPN, with corresponding hazard ratios of 1.14 (95% confidence interval [CI] 1.05–1.23) and 1.15 (95% CI 1.06–1.24) for FPG-CV in the fourth to fifth quintiles and 1.13 (95% CI 1.07–1.20) for HbA1c ≥7%. This finding maintained consistency after excluding potential confounders in the sensitivity analysis, further validating the results.Conclusions:FPG-CV and HbA1c ≥7% were potent predictors of DPN in type 2 diabetic patients. The associations among HbA1c, glycemic variability, and DPN suggest a linked pathophysiologic mechanism, which may play a crucial role in clinical risk assessments.


2011 ◽  
Vol 108 (35) ◽  
pp. 14670-14675 ◽  
Author(s):  
B. P. Cummings ◽  
A. Bettaieb ◽  
J. L. Graham ◽  
K. L. Stanhope ◽  
R. Dill ◽  
...  

Diabetes Care ◽  
2000 ◽  
Vol 23 (1) ◽  
pp. 45-50 ◽  
Author(s):  
M. Muggeo ◽  
G. Zoppini ◽  
E. Bonora ◽  
E. Brun ◽  
R. C. Bonadonna ◽  
...  

Author(s):  
So Young Park ◽  
Chan Hyuk Park

Diabetic neuropathy (DN) is a major complication associated with diabetes mellitus (DM) and results in fatigue. We investigated whether type 2 diabetic patients with or without neuropathy experienced muscle fatigue and determined the most influencing factor on muscle fatigue. Overall, 15 out of 25 patients with type 2 DM were diagnosed with DN using a nerve conduction study in the upper and lower extremities, and the composite score (CS) was calculated. We obtained the duration of DM and body mass index (BMI) from subjects, and they underwent a series of laboratory tests including HbA1c, fasting plasma glucose, triglycerides, and high- and low-density lipoprotein. To qualify muscle fatigue, this study used surface electromyography (sEMG). Anode and cathode electrodes were attached to the medial gastrocnemius. After 100% isometric maximal voluntary contracture of plantarflexion, the root mean square, median frequency (MDF), and mean power frequency (MNF) were obtained. We showed a correlation among laboratory results, duration of DM, BMI, CS, and parameters of muscle fatigue. The duration of DM was related to fatigue of the muscle and CS (p < 0.05). However, CS was not related to fatigue. The MDF and MNF of muscle parameters were positively correlated with HbA1c and fasting plasma glucose (p < 0.05). In conclusion, we suggest that the duration of DM and glycemic control play important roles in muscle fatigue in patients with DN. Additionally, sEMG is useful for diagnosing muscle fatigue in patients with DN.


PPAR Research ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-5 ◽  
Author(s):  
S. Ereqat ◽  
A. Nasereddin ◽  
K. Azmi ◽  
Z. Abdeen ◽  
R. Amin

Peroxisome proliferators activated receptor-gamma2 (PPARγ2) represents the transcriptional master regulator of adipocyte differentiation and therefore has been suggested as a candidate gene for obesity, insulin resistance, and dyslipidemia. The objective of the study was to investigate for the first time the potential association of the most common variant Pro12Ala (p.P12A) substitution of thePPARγ2 gene with body mass index (BMI), blood pressure, fasting plasma glucose, plasma total cholesterol, LDL and HDL cholesterol, and plasma triglyceride in a sample of 202 (138 females and 64 male) type 2 diabetic Palestinians. Genotyping of thePPARγ2 p.P12A polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. The A12 allele was associated with lower fasting plasma glucose (P=.03) but had no influence on blood pressure, BMI, or other metabolic parameters. In obese patients, the p.P12A substitution was associated with elevated total plasma cholesterol levels (P=.02) and a tendency toward increased LDL cholesterol level (P=.06). In conclusion, the p.P12A variant of thePPARγ2 may influence cardiovascular risk through effects on lipid metabolism in obese T2D Palestinian patients.


Sign in / Sign up

Export Citation Format

Share Document